Columbia Technology Ventures
Categories
Search
Collections
Express Licenses
Sign In

Nanobodies for diagnosis, treatment and prevention of infection and disease caused by SARS-CoV-2 and variants

Overview
Request Info
More Like This
Express Licensing

This technology is a library of SARS-CoV-2 specific nanobodies for the treatment, diagnosis, and prophylaxis of COVID-19.

Unmet Need: Effective therapy for and detection of COVID-19 with broad recognition of variants

SARS-CoV-2 is a global public health issue with new variants persistently emerging, demonstrating a need for preventative and therapeutic agents capable of a wide range of recognition while remaining robust and effective. Although monoclonal antibodies have been considered as diagnostics and/or therapeutics, particularly ones that bind the viral spike protein of SARS-CoV-2 or the human angiotensin converting enzyme 2 (ACE2) receptor, they can lack in reactivity, stability, and ease of delivery.

The Technology: Nanobodies with broad recognition against variants of COVID-19

This platform provides a library of human IgG nanobodies against SARS-CoV-2 and its variants. Using previously reported methods for the immunization, isolation, and cloning of nanobodies, this platform will be used to develop nanobodies for the treatment, diagnosis, or prophylaxis of COVID-19. Moreover, the library is designed with a broad repertoire of epitope recognition, encompassing reactivity against a large family of SARS-CoV-2 variants, demonstrating potential benefits over the use of monoclonal antibodies.

Applications:

  • Prophylactic
  • Treatment of SARS-CoV-2
  • Treatment of other coronaviruses
  • Diagnostic assay for COVID-19 and variants
  • Quantifiable detection of polypeptide signaling label
  • Database for nanobody therapeutics against viral infections
  • Research tool for nanobody development

Advantages:

  • Wider epitope recognition
  • Ease of delivery
  • Detection from various biological sample types
  • Robust and effective
  • More stable than monoclonal antibodies
  • Decrease in risk of potential side effects common with monoclonal antibody therapy
  • High-throughput platform for the screening and development of specific nanobodies

Lead Inventor:

W. Ian Lipkin, M.D.

Patent Information:

Patent Pending([WO/20222/66235][(https://patents.google.com/patent/WO2022266235A1/en?oq=PCT%2fUS2022%2f033651))

Related Publications:

Tech Ventures Reference: